Overview

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Status:
Not yet recruiting

Trial end date:
2036-09-18

Target enrollment:

Participant gender:

Summary

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Anastrozole
Exemestane
Letrozole
Tamoxifen